Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045972 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL329193 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL13058644 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL2331995 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL13201892 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL329101 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL4205427 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL329085 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL329165 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL29618100 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104812733-A | A method for the preparation of 3-amino-n-cyclopropyl-2-hydroxyl-hexanamide | JANSSEN PHARMACEUTICA NV | 2015-07-29 | — | — | CN | claimed |
| CN-101454274-B | Processes and intermediates for preparing steric compounds | VERTEX PHARMA | 2014-05-07 | — | — | CN | claimed |
| CN-103772232-A | Method for preparing N-cyclopropyl-3-amino-2-hydroxyhexanamide and derivate thereof | SHANGHAI DESANO CHEMICAL PHARM | 2014-05-07 | — | — | CN | claimed |
| US-20130131359-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | claimed |
| US-8440862-B2 | Process for preparing β-amino-α-hydroxycarboxamides | EVONIK DEGUSSA GMBH (DE) | 2013-05-14 | — | — | US | claimed |
| US-8383858-B2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-26 | — | — | US | claimed |
| CN-102702016-A | Method for preparing 3-amino-N-cyclopropyl-2-hydroxyhexanamide | Zhejiang xinhua pharmaceutical co ltd | 2012-10-03 | — | — | CN | claimed |
| CN-102702015-A | Preparation method of (2S, 3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride | Zhejiang xinhua pharmaceutical co ltd | 2012-10-03 | — | — | CN | claimed |
| CN-102659618-A | Chiral intermediate (S, S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide or its salt and preparation method thereof | CHONGQING PORTON PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-09-12 | — | — | CN | claimed |
| EP-2407448-A2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-18 | — | — | EP | claimed |
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | US | claimed |
| CN-101454274-A | Processes and intermediates for preparing steric compounds | VERTEX PHARMA (US) | 2009-06-10 | — | — | CN | claimed |
| EP-1993993-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2008-11-26 | — | — | EP | claimed |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | claimed |
| WO-2007109023-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | WO | claimed |
| CN-105085310-B | New synthesis method of telaprevir intermediate | 重庆汇智药物研究院有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105085310-B | New synthesis method of telaprevir intermediate | 重庆汇智药物研究院有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20050119189-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-02 | — | — | US | disclosed |
| WO-2005035525-A2 | 2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028502-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | SMYD3 4359/4885METAP1 349/4885METAP2 1514/4885 |
| US-20050119189-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | SMYD3 2822/4885METAP1 57/4885METAP2 277/4885 |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | SMYD3 4359/4885METAP1 349/4885METAP2 1514/4885 |
| US-20130131359-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | REV1, HSD11B1, CYP11B1 | SMYD3 4359/4885METAP1 349/4885METAP2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.